Date | Dividends Paid | Capital Expenditure | Other Financing Activities | Net Cash Used Provided By Financing Activities |
---|
CEO | Mr. Rahul Jayant Nachane |
IPO Date | July 8, 2022 |
Location | India |
Headquarters | 301, E Square |
Employees | 682 |
Sector | Healthcare |
Industries |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin for animal health applications; and nitazoxanide, atovaquone, and ranolazine for human health applications. The company also provides various intermediate products; and finished dosage forms in granules and tablets. NGL Fine-Chem Limited was incorporated in 1981 and is based in Mumbai, India.
Past 5 years
USD 5.36
USD 5.83
USD 27.93
USD 21.77
USD 7.68
StockViz Staff
February 8, 2025
Any question? Send us an email